Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory...

Full description

Bibliographic Details
Main Authors: Helena Iznardo, Lluís Puig
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
psoriasis
pustular psoriasis
psoriatic arthritis
imsidolimab
spesolimab
IL-36
Online Access:https://www.mdpi.com/1422-0067/22/9/4344
id doaj-9e0ac3e9cbc34eb793074aa206a0d77e
record_format Article
spelling doaj-9e0ac3e9cbc34eb793074aa206a0d77e2021-04-21T23:07:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01224344434410.3390/ijms22094344Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic DiseaseHelena Iznardo0Lluís Puig1Dermatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, SpainDermatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, SpainUnmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.https://www.mdpi.com/1422-0067/22/9/4344psoriasispustular psoriasispsoriatic arthritisimsidolimabspesolimabIL-36
collection DOAJ
language English
format Article
sources DOAJ
author Helena Iznardo
Lluís Puig
spellingShingle Helena Iznardo
Lluís Puig
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
International Journal of Molecular Sciences
psoriasis
pustular psoriasis
psoriatic arthritis
imsidolimab
spesolimab
IL-36
author_facet Helena Iznardo
Lluís Puig
author_sort Helena Iznardo
title Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_short Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_fullStr Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full_unstemmed Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_sort exploring the role of il-36 cytokines as a new target in psoriatic disease
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-04-01
description Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.
topic psoriasis
pustular psoriasis
psoriatic arthritis
imsidolimab
spesolimab
IL-36
url https://www.mdpi.com/1422-0067/22/9/4344
work_keys_str_mv AT helenaiznardo exploringtheroleofil36cytokinesasanewtargetinpsoriaticdisease
AT lluispuig exploringtheroleofil36cytokinesasanewtargetinpsoriaticdisease
_version_ 1721515241243672576

Similar Items